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Background: Translational medicine is attracting much attention worldwide and many translational research
organizations (TROs) have been established. In China, translational medicine has developed rapidly, but faces many
challenges. This study was aimed at exploring these challenges faced by emerging TROs in China.
Method: A qualitative, multiple case study approach was used to assess the challenges faced by TROs in China.
Data were collected between May and August 2012.
Results: Eight cases were identified. Overall, four themes that characterized TROs in China emerged from analyses:
1. objectives, organizer, and funding resources, 2. participating partners and research teams, 3. management, and 4.
achievements. All TROs had objectives related to translating basic discovery to clinic treatment and cultivating
translational researchers. In terms of organizer and funding resources, 7 out of 8 TROs were launched only by
universities and/or hospitals, and funded mostly through research grants. As for participating partners and
multidisciplinary research teams, all but one of the TROs only involved biomedical research institutions who were
interested in translational research, and characterized as clinical research centers; 7 out of 8 TROs involved only
researchers from biomedicine and clinical disciplines and none involved disciplines related to education, ethnicity, and
sociology, or engaged the community. Current management of the TROs were generally nested within the traditional
research management paradigms, and failed to adapt to the tenets of translational research. Half of the TROs were at
developmental stages defined as infrastructure construction and recruitment of translational researchers.
Conclusions: TROs in China face the challenge of attracting sustainable funding sources, widening multidisciplinary
cooperation, cultivating multi-disciplinary translational researchers and adapting current research management to
translational research. Greater emphasis should be placed on increasing multidisciplinary cooperation, and innovating
in education programs to cultivate of translational researchers. Efforts should be made to reform research management
in TROs, and establish sustainable funding resources.
Keywords: Translational medicine, Translational research organization, Translational medical center, Case studyIntroduction
Translational medicine/research/science has become
an issue of increasing importance to scientists and
governments around the world. The history of translational
medicine can be traced back to 1966, when the notion of
“From bench to bedside” was presented in Bioscience [1].
The concept of “bench to bedside” was further raised in* Correspondence: Changkun03@aliyun.com
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reproduction in any medium, provided the or1992 in the journal of Science [2], and in 1996s, the concept
of “translational research” was presented in the Lancet [3].
Dr. Elias Zerhouni, former Director of the United States
National Institutes of Health (NIH) defined the term
"translational medicine" for the first time in 2003 [4].
Scientists have conducted successful studies in many
areas of translational medicine [5-8] and the scope of
translational medicine/research/science is evolving and
enlarging [9-17]. The overall goals of the “translational”
approach are to translate between basic science research
and practice in novel diagnostics/prognostics/therapeuticstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulations and public policies to influence basic research
[17,18]. Translation research is a biomedical research
translation continuum that includes 4 practical landmarks
(basic science discovery, proposed human application,
proven clinical application, and clinical practice) which
corresponds to the three translation chasms often referred
to as T1 (defined as from basic science to clinical science),
T2 (defined as from clinical science to clinical practice),
and T3 (defined as from clinical science to health
improvements) [13]. The complete translation continuum
is a complex process and takes an average of 17 years for
research evidence to reach clinical practice [11]. Given the
time and complexity of translating findings into care, there
is a continued need to promote the concept of translational
medicine among clinicians, basic science researchers,
biotechnologists, politicians, ethicists, sociologists, and
investors and to further improve efficiency of these
translational processes [19].
The past three decades have witnessed tremendous
advances in China in terms of living conditions, food,
nutrition, and health systems reform [20]. However,
while the economy grows and the society rapidly
transforms, the healthcare system still faces multiple
problems [20]. Communicable diseases such as hepatitis B
virus, tuberculosis, and HIV remain a heavy burden, while
at the same time, chronic diseases, including cancer,
cardiovascular disease, hypertension, and diabetes mellitus
have emerged as leading causes of mortality and disability
in China [20]. Along with accelerating economic growth,
China is experiencing rapid population aging [21]. Soaring
health needs and limited health resources as a result of an
aging population, shifts in disease patterns, and failure of
the health market indicate that it is urgent for China to
develop strong translational medicine programs to move
efficacious interventions into the health care delivery
system. Fortunately, with the support of governments
and scientists, translational medicine in China has been
developing rapidly in recent years [20,22-28].
To promote translational research, it is required that
nations set up translational research organizations (TROs)
and integrate them into the larger network of bench to
bedside translation continuum [28]. In countries with
developed translational medicine, such as the U.S., the
government has funded a network of translational science
institutes or centers from national to state levels across
the country [29]. In China, many TROs have been
established or have been in the process of development
since 2009. However, translational medicine has met a lot
of challenges in China. The aim of this study was to
understand the challenges facing translational medicine in
China in order to gather information that may inform
the creation of more efficient organizational structure,
functions, and performance of Chinese TROs.Method
Case studies have a major function in generating hypoth-
eses and building theory [30]. Usually, better understanding
of a phenomenon is gained by conducting multiple case
studies [31]. Multiple case studies enable the researcher to
explore differences within and between cases in order to
deeper insight into phenomena of interest [31,32]. A
qualitative multiple case study design was used to examine
the construction and performance of TROs in China and
was conducted between May and August 2012.
Definition of TROs
In this study, TROs refers to institutes explicitly with the
title of ‘Translational Medical Center’; these centers
have a multidisciplinary research group (basic and clinic
researchers, statisticians, psychologists, educators and
sociological researchers) who work as a team aimed at
translating basic discovery to disease diagnosis, treatment,
and prevention, or population health promotion, while
simultaneously cultivating translational researchers.
Case selection
TROs were selected if they met the following criteria: (1)
had the designation of a translational medical center,
translational research center or translational medical
research center; (2) had a multidisciplinary research team
including representatives from basic medicine, clinic medi-
cine, statistics, psychology, and social sciences; (3) aimed at
translating basic discovery to diagnosis, clinic treatment,
prevention, or population health promotion, (4) aimed at
cultivating translational researchers; (5) had representations
from hospitals and/or universities; (6) had representations
from a wide economic and geographic spectrum through-
out China, and (7) established before January 2012.
Data collection method
Data was triangulated by integrating interviews and
review of secondary sources.
(1) Interviews: The purposive sampling technique
(based on the afore-mentioned inclusion criteria) was
used to select TROs for interview. We used an interview
guide to collect data on year of establishment, objectives
of TROs, funding resources, research teams (including
multidisciplinary and institutional), management teams
and approaches, and achievement (platform establishment,
translational scientist cultivation, funding, cooperation, and
translational research outcomes).
(2) Review of secondary sources: Google, Google Scholar,
and PubMed were used to search related literature and
reports published up to May 31st, 2012, on Chinese TROs.
Search terms included translational research center in
China, translational medical research center in China, and
translational research institution.
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documents from the 2012 Sino-American Symposium
on Clinical and Translational Medicine (SAS-CTM).
Data analysis
We combined qualitative data from all sources and ana-
lyzed them using qualitative content analysis method
[30]. The analysis included three phrases: preparation
(reviewing the data), organization (coding, categorizing,
and triangulating the data), and cross-case synthesis. The
main themes that emerged following data coding included
date of setup for the TROs, objectives of the TROs, or-
ganizer, funding sources, participating partners and
multidisciplinary research teams, management (team, pro-
ject management, cooperation, and funding), and achieve-
ments (infrastructure establishment, research team
establishment, translational research, service, and out-
comes including publications, awards, intellectual
properties, products, and international communica-
tion) (Additional file 1).
Results
General information on cases
In total, 8 TROS were identified. They included TROs
distributed in the north, south, west, and east of China, in
both high and low income regions (Figure 1). Characteris-
tics of the 8 TROs are presented in Table 1. All of theFigure 1 Distribution of cases in this study. This figure is a description oTROs were established between 2008 and 2011: two in
2008 and 2009, respectively, four in 2010, and two in
2011. Among them, one was set up as an independent
college (College of Translational Medical Research
(CTMR) of the first hospital of Zhejiang province);
the rest were set up as Translational (Medical) Research
Centers. Four cases were located in teaching hospitals
affiliated with universities, three were located in universities,
and one was located in a non-teaching hospital (Table 1).
Data from CTMR in the Zhejiang province was collected
only by interview. In three cases, data was collected by
using both interviews and reports. In three cases, data were
obtained from reviewing documents from both the 2012
Sino-American Symposium on Clinical and Translational
Medicine (SAS-CTM) and published reports; finally,
data from Peking Union Medical College Hospital
(PUMCH) was collected by a study of literature and a
review of reports (Table 1).
Objectives, organizer and funding sources of TROs
All of TROs focused on facilitating translation between
clinical and basic researchers (promoting clinic-basic
multidisciplinary cooperation) and cultivating translational
scientists. However, few TROs explicitly stated any consid-
eration about translating research into health policy and
public health (Table 2). Except for one TRO, which was
launched through a joint effort of the government and af the distribution of cases in this study.
Table 1 General information of cases
TROs Year of construction Location Methods of data collection
PUMCH-TMC 2010 Teaching Hospital Literature and report [33,34]
CTMR of the first hospital of Zhejiang province 2010 University Interview
TMRC of Children’s hospital of Fudan University 2008 Teaching Hospital Interview and report [35]
TRCSR in Shanghai Ninth hospital 2011 Hospital Document review and report [36]
TMRC of North East of China 2010 University Document review and report [37]
East TMRC of Tongji University 2010 University Document review and report [38]
TMRC of Wuhan Union Hospital 2011 Teaching Hospital Interview and report [39]
TMRC of West China Hospital 2009 Teaching Hospital Interview and report [40]
Notes: TROs refers to translational research organization; PUMCH refers to the Peking Union Medical College Hospital; TMC refers to translational medical center;
CTMR refers to College of Translational Medical Research; TRCSR refers to Translational Research Center of Stem Cell and Regenerative Medicine.
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were launched by universities and/or hospitals. As for
funding sources, most of the TROs were funded by
partners within TROs or through research grants.
Only East TMC of Tongji University was supported
by the local government but not the central government.
CTMR of the Zhejiang province was awarded funds from
social services agencies (Table 2). It was notable that no
TROs had funding from industry.
Organizations of TROs
We collected data about collaborating partners and
multidisciplinary research teams involved with the respect-
ive TROs. As for partners, East TMC of Tongji University
included a university, a hospital (Shanghai East Hospital),
and government organizations such as the Pudong New
District and Technology Committee and the Pudong New
District Health Bureau. The remaining seven TROs
were comprised of only research institutes and hospi-
tals. Regarding multidisciplinary research teams, only
TMC of Wuhan Union Hospital included public health;
the other TROs involved researchers from biomedical and
clinical disciplines, with no public health involvement.
None of the TROs involved disciplines related to educa-
tion, behavioral sciences, and sociology, or engaged the
community (Table 3).
Management of TROs
We focused on management teams and research groups,
funds, and projects. In terms of management teams, all
but one TRO (CTMR of the first affiliated hospital of
Zhejiang Province) had a director, vice director, and
an administration office. In addition, all TROs had
various committees, including a management committee,
an academic committee, and a consulting committee
(Table 4). Regarding team management, all TROs paid
most attention to recruiting researchers, setting up
principal investigators (PI), and nurturing translational
researchers (through continuing education, joint-cultivationof graduates, training, and academic visits). There was no
specific strategy to cultivate multi-disciplinary translational
researchers and there were no Master's or PhD de-
gree programs in translational medicine in any of the
TROs (Table 5).
Overall, TROs in China used both internal and exter-
nal collaborators. As for internal collaboration, one TRO
(TMC of Children’s Hospital of Fudan University) had a
policy on internal cooperation across institutes and focused
on sharing resources and intellectual property, as well as on
joint publications. Two TROs (PUMCH-TMC and CTMR
of the first affiliated hospital of Zhejiang province) started
international cooperation with universities in the U.S. to
educate translational researchers. Two TROs (CTMR of
the first affiliated hospital of Zhejiang province and TMC
of Children’s Hospital of Fudan University) attracted local
government funding (Table 5).
Most TROs, however, had no specific strategies for
education programs related to cultivation of translational
scientists, faculty promotion or performance assessment,
promotion of multidisciplinary cooperation inside and
outside, or evaluation of outcomes of the different stages
across translational continuum. Only the CTMR of the
first affiliated hospital of Zhejiang had a policy about
performance evaluation, organizing experts locally and
abroad to evaluate TRO performance every 3 years
according to a list of fixed goals (Table 5).
Achievements of TROs
A majority of TROs are at the beginning stage, few had
experienced substantial achievements as TROs. Their main
achievements had been predominantly infrastructure con-
struction and recruitment of translational researchers.
Three TROs carried out international collaboration. Some
TROs had created products such as implantable ventricular
assist device (VAD), published papers (Forty-three papers
in SCI journals), and/or received awards or patents. Only
TRCSR provided a service for training translational
researchers in 2012 (Table 6).
Table 2 Objectives, organizer and funding resources of TROs
TROs Objective Organizer Funding resources
PUMCH-TMC To provide a robust platform for translational medicine
research programs (to provide consulting services and
technical support to researchers, create more collaborations
and partnerships) and provide post-graduate education.
With consistent effort, the PUMCH-TMC aims to become
a national and international translational medicine institute
Hospital No data
CTMR of the first hospital
of Zhejiang province
To assist cooperation between basic and clinical research,
provide support for translation and cooperation, and innovate
management to realize cooperation of research groups
University Funded by social
organizations and
institutes in CTMR
TMC of Children’s hospital
of Fudan University
To be become the national or Asian center of child medicine
and medical teaching and research and to facilitate the
integration of basic and clinic research
University Funded by research grants
and institutes in TMC
TRCSR To assist multidisciplinary cooperation, cultivate translational
scientists, and provide a platform of domestic and international
translational research in the field of regenerative medicine
Hospital Funded by research grants
and institutes in TRCSR
TMC of North East of China To integrate basic research, clinic medicine, and bio-industry;
cultivate translational scientists; form a translational medical
research network; integrate preclinical medicine, clinical
medicine and drug development; establish open and
cooperative networks in Northeast China; and develop
medicine, disease diagnoses, and strategies for treatment
University Funded by research grants
and institutes in TMC
East TMC of Tongji University To integrate government, enterprise, education, research,
and medicine; promote integration of basic and clinic
care; prioritize the development of translational medical
research as the primary task, adhering to the operation
mode of “political, industry, education, research and
medical field”; and fully integrate with advanced clinical




Funded by research grants
and local government
TMC of Wuhan Union
Hospital
To bridge basic, clinical, and bio-industry in order to
promote new technology, products, and drugs;
promote multidisciplinary cooperation; and cultivate
translational scientists
University Funded by research grants
and institutes in TMC.
TMC of West China Hospital To promote cooperation between basic research and
clinical care, support outcome translation, insist on
research-education-industry cooperation, and encourage
this center and industry to participate in translational
research by a joint-stoke model.
University Funded by research grants
and institutes in TMC
Notes: TROs refers to translational research organization; PUMCH refers to the Peking Union Medical College Hospital; TMC refers to translational medical center;
CTMR refers to College of Translational Medical Research; TRCSR refers to Translational Research Center of Stem Cell and Regenerative Medicine.
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Translational medicine has been supported by the Chinese
government. The Chinese government has encouraged
integrating industry-academic-research [22]. The 12th
Five-year Socio-economic Development Plan (2011–2015)
in China emphasized improvement of medical research
through developing translational research [20]. The Me-
dium and Long Term Science and Technology [S&T]
Development Plan (2012–2030) issued in 2013 also in-
cluded emphasis on translational medicine [41]. However,
while the Ministry of Science and Technology has just
supported a project for building a platform of clinical
resources [22], translational medicine in China is still in
its early stages. This case study revealed that TROs face
many challenges including: 1) They were launched by bio-
medical research institutions and are characterized as
actual clinic research centers; 2) TROs are not integratedwith educational programs that are designed to furnish
the TROs with qualified translational researchers; 3) TROs
Lacked sustainable funding sources; 4) TROs lacked
robust management structures.
Most TROs were launched by bio-medical research
institutions and are characterized as actual clinic research
centers. Although there are some significant translational
research occurring outside of government support, such as
industries (e.g., pharmaceutical companies, CROs) and
foundations/NGOs [42], internationally, governments plays
great role in planning, organizing and funding translational
research. In the US, National Institutes of Health (NIH)
launched the Clinical and Translational Science Awards
(CTSA) and established the National Centre for Advancing
Translational Sciences (NCATS) [43]. Government estab-
lishments such as the Medical Research Council (MRC) in
the UK [44,45], the French National Research Agency
Table 3 Organization of TROs
TROs Partners Research team
PUMCH-TMC Institute of Basic Medical Science of the
CAMS, PUMC, and Institute of Pathogen
Biology of the Chinese CAMS
Fifty academicians from areas of regenerative
therapy using stem cells for central nervous
system diseases, the integrated study of the
clinical features and molecular mechanisms
of pancreatic cancer, HIV/AIDS, chronic
metabolic diseases (diabetes, rheumatologic
diseases, and the diagnostic and therapeutic
use of allergens)
CTMR of the first affiliated hospital of
Zhejiang province
Department of neuropsychological disease,
gastrointestinal tumor, cardiovascular disease,
reproductive health, kidney disease, visual
reconstruction, hemopoietic disease and
stem therapy, and laparoscope technology
Twenty-thirty PIs and research groups from the
above departments
TMC of Children’s Hospital of Fudan Univeristy Children’s Hospital, Biomedicine Research
Institute, and the Institute of Developmental
Biology and Birth Defects
Ten to 15 research groups with 15–25 principle
investigators (PIs), 25–30 research assistants
from the areas of pediatrics, developmental
biology, and birth defects
TRCSR Shanghai Ninth People’s Hospital Researchers in tissue engineering and stem
cell therapy
TMC of North East of China Dalian Institute of Chemical Physics,
Chinese Academy of Sciences, and
Harbin Medical University
Researchers from the Department of Biotechnology
of Dalian Institute of Chemical Physics including
Drug Separation, Analytical Chemistry, Medicinal
Biotechnology, Biomaterials and Biotechnology,
Energy, and Environmental Biological Technology
East TMC of Tongji University Pudong New District and Technology
Committee, Pudong New District Health
Bureau, Tongji University, and Shanghai
East Hospital
Forty-one staff members, including 36 full-time
personnel and 15 PIs in the area of cardiovascular
diseases, inflammation and tumors, psychosomatic
diseases, and trauma emergency treatment
TMC of Wuhan Union Hospital Huazhong University of Science and
Technology, Wuhan comprehensive
drug research and develop platform,
innovative biomedical-clinic research
platform, and Wuhan Biolake
Clinical medicine, basic medicine, public health,
pharmacy, and bioscience
TMC of West China Hospital West China hospital A total of 1,000 researchers from clinical medicine,
pharmacy, biotechnology, chemistry, and
materials science
Notes: TROs refers to translational research organization; PUMCH refers to the Peking Union Medical College Hospital; TMC refers to translational medical center;
CTMR refers to College of Translational Medical Research; TRCSR refers to Translational Research Center of Stem Cell and Regenerative Medicine.
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Council (NHMRC) in Australia [47], and the Canadian
Institutes for Health Research (CIHR) [48] guided
translational medicine in these countries. In China,
the government encouraged construction of TROs,
and a number of TROs have been established since
2009 [49]. Many hospitals are setting up translational
medicine centers without the necessary infrastructures,
robust management systems and government support that
characterize TROs in high income countries [22]. China
lacks a national systematic plan and a national transla-
tional research center to build a roadmap for deployment
of effective translational medicine. We found that most
Chinese TROs were launched by groups of research
institutions without specific government participation in
organizing, funding, and coordinating although all of TROs
were established in public institutions which have signifi-
cant government support for their activities. TROs, asmultidisciplinary entities, offer the potential to bring to-
gether different perspectives to address otherwise intract-
able problems [50]. Clinical and Translational Science
Centers (CTSCs) in the U.S. widely involve institutes and
disciplines, and the various CTSA programs throughout
that country are all closely linked [51]. The CTSCs incubate
multidisciplinary, cooperative programs that include trans-
lational technologies, resources, and novel methodologies;
biostatistics; study design and research ethics; participant
and clinical interaction resources; community engagement,
education, regulatory knowledge and support; informatics;
and pilot and collaborative studies [51]. However, we report
that TROs in China are characterized as clinical research
centers. In addition, most TROs just translate basic re-
search outcomes to clinical practice However, very few
TROs involved disciplines related to public health, educa-
tion, ethnicity, and sociology; engaged the community; or
provided training for translational researchers.
Table 4 Management team in TROs
TROs Leader Committee Others
PUMCH-TMC Director of TMC Expert committee: Two honored directors,
1 director, five associate directors, and
forty-three committee members
No data
CTMR of the first affiliated
hospital of Zhejiang province
One dean and one
vice-dean
Expert committee: Participants from the
university, basic medicine, and the hospital
Management office: To carry out administration
PI: One PI in each research area




Academic committee, human resource
committee, resource and technological
platform management committee
Administration office: One-two secretaries
TRCSR Expert committee: Overall planning, projects
and budget review, stage and final assessment)
Office of Translational Research Center:
Project management, professional staff
training in translational medicine, website
managementOrganizing committee: To establish an efficient
and timely information network and provide
efficient services; to assist the expert committee
with reviewing and revising projects and budgets;
to coordinate project implementation
TMC of North East of China One director Management committee: One honorary
director, one director, one vice-director,
ten committee members
No data
East TMC of Tongji
University
One director Academic Committee, Management Committee,
and Advisory Panel (composed of representatives
from “political, industry, education, research,
and medical fields”)
Research Center Management Office: To be
responsible for day-to-day management and
liaison work.





Academic committee: One director,
several deputy directors, and a committee
Management Office: One director and two
secretaries, to be responsible for day-to-day
management
TMC of West China Hospital One director No data No data
Notes: TROs refers to translational research organization; PUMCH refers to the Peking Union Medical College Hospital; TMC refers to translational medical center;
CTMR refers to College of Translational Medical Research; TRCSR refers to Translational Research Center of Stem Cell and Regenerative Medicine.
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translational researchers for TROs
The importance and difficulties of recruiting, mentoring,
and retaining an international assembly of qualified
clinical and translational scientists has been recognized
[52]. Addressing the nurturing of translational investigators,
the Association of American Medical Colleges convened its
second Clinical Research Task Force (CRTF II) in 2006 and
underscored the importance of requiring all future physi-
cians to be educated in the principles and methodologies of
translational and clinical research [53]. CRTF II suggested a
degree program (Master’s level training at a minimum)
[53]. Many CTSC programs provide PhD and Master's
degrees [54-56]. In addition, CRTF II suggested start-up
support for junior translational investigators, accelerated
training, and modifying training (K23 and K24) awards to
nurture translational investigators [53].
Translational medicine is likely to have a profound
impact on future medical education in China, and the
purposeful training of translational research will need to
be developed [22]. We report that although most of the
TROs had the objective of education, the concept of
multidisciplinary researcher cultivation was limited tobasic and clinical medicine instead of broader disciplines
such as sociology, management, law, public health, and
social sciences. What’s more, China has no Master's or
PhD degree programs in translational medicine to date.
TROs Lacked sustainable funding sources
Successful translational research will require substantially
more money, an important part of which is government
funding. For example, CTSAs provided $500 million
annually to 60 translational medical centers throughout
the U.S. [6]. The MRC UK committed £250 million to
deliver this important part of its mission [44]. In addition,
CTSCs attract funds from enterprises and social agencies
[57]. In China, government increased and is increasing
investment to translational research; the National Natural
Science Foundation of China approved a budget of 18.27
billion RMB (approximately 2.9 billion USD) for fiscal year
2011 for translational research, which was an 89% increase
from 9.65 billion RMB (approximately 1.52 billion USD)
from fiscal year 2010. Recently, translational research has
been included in certain government projects, such as the
National High Technology Research and Development
Program (863) and the National Basic Research Program
Table 5 Management of TROs
TROs Researcher management Project management Cooperation Others
PUMCH-TMC Recruiting part-time or full-time
translational scientists at home
locally and abroad
No data Cooperating with the University of




CTMR of the first affiliated
hospital of Zhejiang
province
Recruiting part-time or full-time
translational scientists at home
and abroad, setting up PI
Project selection by expert committee
and PI (CTMR provides platform), shared
resource seed funds for selected projects
Exploring cooperation with institutes
outside CTMR by setting up research
alliances, joint laboratories, and shared
grants. Setting up policies about
publications and intellectual property
across institutes. Setting up cooperation
with the University of California, Los Angeles
Performance evaluation: CTMR
organizes experts at home and
abroad to evaluate TRO performance
every 3 years according to a list
of fixed goals
Shared source management: Open
to all researchers freely, paid for the
source which bought by researcher
group themselves before.
Funds: Attract funding from provincial
and national governments
TMC of Children’s hospital
of Fudan University
Recruiting part-time or full-time
translational scientists at home
and abroad, exchanging translational
researchers, jointly cultivating
graduates, setting up PI
No data Training of translational researchers Funds: Attract government funds
TRCSR Arrange qualified medical professional
and management personnel to attend
related courses in a planned and
purposeful manner
To organize the expert committee for the
planning, discussion, revision and evaluation
of each project, and coordinate the project
implementation; to establish an information
network for the project; to assist in the
application of clinical trial; to organize
the investigation, application, and
screening of the project, and submit
them to the expert committee for
further consideration.
No data 3-year Goals: Recruit translational
scientists, train translational
researchers, translate 3 to 5
projects to clinical practice,
build up a Sino-Australian
collaborative laboratory
TMC of North East of
China
No data No data No data
East TMC of Tongji
University
Developing translational researchers by
visiting, continue education, academic
cooperation, joint-cultivating PhD
No data External Cooperation: Mutual visits,
joint training program for doctoral
students, advanced study of staffs,
scientific research cooperation and co-host
international academic conferences
No data
TMC of Wuhan Union
Hospital
Setting up PIs policy and academic
committee review the PIs
No data Researchers management:
TMC of West China
Hospital
Setting up policy for recruitment of
translational scientists
No data Management of cooperation and
intellectual refers to policy/approach
in the West Sichuan University
Funds: Application of research grants
Notes: TROs refers to translational research organization; PUMCH refers to the Peking Union Medical College Hospital; TMC refers to translational medical center; CTMR refers to College of Translational Medical

















Table 6 Achievements of TROs
TROs Infrastructure Researcher group Translational research Others
PUMCH-TMC Platform establishment Researcher recruitment mode No data International cooperation: Starting translational
researcher cultivation with UCSF
CTMR of the first
affiliated hospital
of Zhejiang province











TRCSR construction of the state
of art GMP standard laboratory
No data Select the first 15 translational projects,
Independent design and commercialization of
reagents for embryo verification and warming
Service: successfully held the first and
second phase of training workshop in
March and May, 2012; held the golden
symposium in April 2012.
TMC of North East of China Six platforms were established No data Studying on cardiovascular diseases, brain
glioma, Qualifying the hospital drug preparations,
Screening and development of new drugs, micro
RNA delivery system.
No data
East TMC of Tongji University Currently, six key technology
functional units have been
established. Two more functional
units has been launched in 2012
and will be established
No data It achieved great success in the development
of implantable ventricular assist device (VAD) and
the study of its treatment in end-stage heart failure;
Undertaken 35 authorized clinical drug trial from
enterprises.x
Research funds: 17.35 million Yuan
research funds
Outcome (Papers, awards, patent): Forty-three
SCI papers were published as the first author
or corresponding authors; the Center has won
4 technology achievement awards; Submitted
3 applications of. National invention patent.
International cooperation: Established









platforms for the drug
research and translational research
Organized researcher groups No data International cooperation: NIH-TMC of
West China Hospital international
Symposium in 2011.
Signed contract with several drug enterprises,
Notes: TROs refers to translational research organization; PUMCH refers to the Peking Union Medical College Hospital; TMC refers to translational medical center; CTMR refers to College of Translational Medical
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http://www.translational-medicine.com/content/11/1/256(973) [22]. Projects with potential translational research
are strongly encouraged and have priorities over more
speculative applications [28,58]. The government is
making investments into organizations that focused
on translation such as Beijing Genomics Institute
(BGI) [59] and Genzyme of Cambridge, Massachusetts
and Tianjin International Joint Academy of Biotechnology
and Medicine (TJAB)) [60]. However, this study found that
in at least these 8 TROs, funds mainly came from research
grants or partners of TROs. The government allocated
little special funds to TROs construction or researcher
cultivation as CTSAs did. Besides, social entrepreneurship
is relatively new in China and its concept was first intro-
duced through various symposiums and conferences in
2004. In 2012, 54% of surveyed social enterprises in China
are under 3 years old, of which 21% are less than 1 year
old, and 38% were older than 5 years. Compared to 2011
survey, the number of mature social enterprises increased
from 15% in 2011 to 38% in 2012 [61]. Thus, TROs in
China seldom attract funds from social enterprises or
donors. Therefore, a sustainable funding mechanism is one
major challenge facing translational research in China.
Chinese TROs lacked appropriate management
The translational continuum is a complicated process, in-
cluding many steps and involving multidisciplinary research
teams that interact with each other across the continuum
[62,63]. Management in TROs has the function of obtaining
funding, monitoring, guiding and providing shared sources,
promoting multidisciplinary collaboration/cooperation for
translational research [64]. To meet the needs of transla-
tional medicine, current scientific research management
teams should adapt to the tenets of translational research
[22]. For example, the centralization of CTSCs in the U.S. is
one way to remove organizational barriers, and 58% of
CTSCs are moving toward administrative centralization
[53]. A flexible framework for performance assessment that
tracks progress and incentivizes fruitful activities is very
important for cost-effective translational research [64].
However, there is no consensus on the methodologies or
frameworks for assessing TROs performance [65]. Although
we indicated that most TROs in China had established
management teams, specific measures in the following areas
were still lacking: developing and nurturing researchers,
promoting multidisciplinary cooperation, conducting per-
formance assessments, and offering incentives for partners.
TROs also lacked mechanisms for profit- and property-
sharing, cost-effectiveness assessment systems across dif-
ferent stages in the translational research continuum, and
conceptions of “providing service.”
Implications for practice and research
Results of this study had the following implications for
future practice in China.TROs in China need to increase multidisciplinary
cooperation
Multidisciplinary research teams in translational research
span the life sciences, social sciences, and the physical
sciences. The recruitment of sufficient and appropriate
participants for translational medicine requires TROs to
collaborate with their communities [53]. Furthermore,
translational medicine entails not only a “from-bench-
to-bedside” approach but also preventive medicine and
public policy [17,18]. Community engagement and the
broadening of disciplines and research teams in social
sciences, physical sciences, health policy, and public
health should be emphasized by Chinese TROs.
Medical education needs innovation
Translational researchers must have multidisciplinary
knowledge and capability [66].Translational researchers
need to have the collaboration skills to allow ensure
clinicians and scientists to function in effective inter-
professional, multidisciplinary teams [67]. Therefore, current
medical education program must be tailored towards
training multidisciplinary translational researchers in
order to achieve the full benefits and promising applications
of translational medicine [68]. China has begun cultivating
interdisciplinary talent recently; this cultivation has
developed slowly [69]. Although present medical edu-
cation programs, including 8- and 5-year programs,
have the potential to cultivate medical students with
both clinical research and basic research [28], they cannot
provide multidisciplinary knowledge wider than medical
knowledge because, in the traditional Chinese university
model, colleges of different disciplines seldom communi-
cate with one another [22]. Therefore, current medical
education needs innovation, such as launching Master's
or PhD degrees in translational medicine by the Minis-
try of Education which emphasize professional incubation
to generate future-leading, multidisciplinary translational
scientists in TROs.Exploring appropriate management of TROs is of crucial
importance
Effective management can ensure the overall excellent
performance of TROs [53,70]. Translational research is
particularly complex and requires a scalable and adap-
tive management approach [71]. At the early stages of
Chinese TROs, it is particularly important to explore
management models that include creating a “culture” of
multidisciplinary cooperation in TROs, medical schools
and their affiliated teaching hospitals; construct a
flexible performance assessment system that considers
both translational research and academic recognition
in researchers' performance assessments; and explore
sustainable funding resources.
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http://www.translational-medicine.com/content/11/1/256Translational research in health policy should be
emphasized in China
As in most countries, health research and policy making in
China usually operate in separate environments, each with
its own professional culture, and most public health
research stops at publication [71]. As a result, many public
health policies in China are not based on high-quality
evidence. A platform using TROs for bilateral com-
munication between researchers and policy makers is
needed to improve mutual understanding and to es-
tablish an effective and efficient dialogue channel.
Translational research in health policy that can pro-
mote evidence-based health policies [18,71] should be
underscored in China.
Strengths and limitations
A major strength of the case study approach is the
opportunity to use multiple sources of evidence such
as interviews and document reviews [32]. The main
limitation is that we collected data about some cases
indirectly through conferences, reports, and literature,
some of which may have been incomplete. A qualita-
tive multiple case study method was used to collect data,
which as a form of qualitative descriptive research, looks
intensely at an individual or small participant pool, draw-
ing conclusions only about that participant or group and
only in that specific context. In this case, we did not
focus on the discovery of a universal, generalizable
truth, nor did we look for cause-effect relationships;
instead, we placed emphasis on exploration and
description [72].
Conclusions
Establishing TROs is an important approach in promot-
ing tranlationational medicine. TROs should be coopera-
tive platforms, centers for human resource cultivation
(translational researchers) and agencies of social services
(consulting and training) and translational research.
Translational medicine in China is developing quickly,
and many TROs have been established throughout the
country. However, while these TROs maintain key staff
(academic, program and administration, technical, and re-
search), headquarters and office accommodation, and suit-
able experimental research facilities, they still face many
challenges. Therefore, it is of paramount importance to
strengthen the government's role in widening multidiscip-
linary cooperation, promoting translational researcher cul-
tivation, and designing management approaches that
foster an open culture of cooperation.Additional file
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